ArticleBiosensors2026
A Weighted Neural Network Model Based on Laboratory Tests for Identifying Lymph Node Metastases in Esophageal Squamous Cell Carcinomas.
Article in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Lymph node metastasis (LNM) is a key prognostic factor in esophageal squamous cell carcinoma (ESCC), and accurate preoperative prediction remains challenging. Blood biomarkers provide a conventional, preoperative diagnostic technique that is cost-effective and free from radiation risks. So far, previous studies have been published on the precise diagnosis of lymph node metastases using conventional ultrasound or CT techniques. While there is a lack of research studies that address the diagnosis of LNM from blood biomarkers. In this work, we acquired a cohort of blood biomarkers of 1933 patients and designed a weighted neural network (WNN) model for the accurate prediction of LNM from blood biomarkers. The WNN model is designed with a neural network classifier trained on blood biomarkers labeled with pathological nodal (pN) stages of LNM. The experimental findings demonstrate that the WNN model achieved 83.1% accuracy and an AUC of 0.88 on the original, non-augmented test set for diagnosing LNM, while CT only achieved 50.4% accuracy (AUC 0.60) and ultrasound achieved 60.5% accuracy (AUC 0.67). Additionally, SHAP analysis reveals that three blood biomarkers-white blood cells (WBC#), monocytes (Mono#), and neutrophils (Neut#)-significantly impact the WNN model's output. This WNN model shows promise as a research tool to diagnose LNM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.